NCT01950065已完成不适用
Effectiveness and Safety Study of the Iovera Device for the Temporary Reduction in the Appearance of Forehead Wrinkles
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 85
- 试验地点
- 11
- 主要终点
- Improvement on the 5-point Wrinkle Scale
研究概览
简要总结
Evaluate the effectiveness and safety of the iovera device for the temporary reduction in the appearance of forehead wrinkles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18 to 65 years
- •Subject has a forehead wrinkle rating by the Investigator/designee of at least "2" in full contraction on the 5-point Wrinkle Scale (5WS) as rated by the study Investigator, which, upon physical manipulation/separation of the skin, demonstrates a reduction in wrinkle severity
- •Subject has a glabella wrinkle rating by the Investigator/designee of at least "1" in full contraction on the 5-point Glabella Scale (5GS)
- •Subject has at least a 2 point difference between resting and dynamic forehead wrinkle scores using the 5-point Wrinkle Scale (5WS) as rated by the Investigator/designee
- •Subject has Fitzpatrick Skin Type I, II, III, or IV (see Error! Reference source not found.)
- •Subject understands and commits to comply with study requirements
- •Subject is in good general health and free of any condition that could impair either complete study participation or evaluation of forehead wrinkle rating
- •Subject is willing and able to give written informed consent
排除标准
- •Subject has a clotting disorder or coagulopathy that requires regular use of an anticoagulant and/or antiplatelet therapy (e.g., warfarin, clopidogrel, etc.)
- •Subject has used aspirin or any non-steroidal anti-inflammatory drugs (NSAIDs) within seven (7) days prior to screening or use of the device
- •Subject has had prior surgery that alters the subcutaneous anatomy of the target treatment sites
- •Subject has undergone another surgical cosmetic procedure or botulinum toxin injection at or above the level of the zygoma (cheekbones) within the past six (6) months prior to screening
- •Subject has a resting wrinkle score of "3" or higher on the 5WS as rated by the study Investigator
- •Subject actively elevates forehead during rest
- •Subject has been treated with any fillers listed in Error! Reference source not found. in the temple or forehead area in the time intervals specified prior to screening
- •Subject has any of the following conditions:
- •Dermatochalasis with <2mm lid margin when looking straight ahead
- •Excessive skin laxity/skin aging
- •Asymmetry in the upper face
- •History of facial nerve palsy
- •Eyebrow or eyelid ptosis
- •History of neuromuscular disorder
- •Chronic dry eye symptoms
- •Allergy or intolerance to local anesthetic agents (e.g., Lidocaine)
- •Use of narcotic medications for a chronic pain condition
- •Other clinically significant local skin condition (e.g., skin infection) at target treatment site
- •Any physical or psychiatric condition that in the Investigator's opinion would prevent treatment or adequate study participation
- •Chronic medical condition that in the Investigator's opinion would affect study participation (such as diabetes, hepatitis, HIV, etc.)
- •Known diagnosis of cryoglobulinemia, paroxysmal cold hemoglobinuria, or cold urticaria
- •Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the Investigator
- •Fitzpatrick Skin Type V or VI (see Table 3)
- •Subject currently enrolled in an investigational drug, biologic or device study that could affect the safety or effectiveness of wrinkle treatment
结局指标
主要结局
Improvement on the 5-point Wrinkle Scale
时间窗: 30 Days
次要结局
未报告次要终点
研究者
研究点 (11)
Loading locations...
相似试验
已完成
不适用
Study to Evaluate the Iovera° Device for Temporary Relief From Knee PainKnee OsteoarthritisNCT02260921Pacira Pharmaceuticals, Inc180
已完成
不适用
Efficacy And Safety of An IRE System For Treatment of Inferior Turbinate HypertrophyInferior Turbinate HypertrophyNasal ObstructionHypertrophy Mucous Membrane TurbinateNCT06438185ENTire Medical Ltd.48
已完成
不适用
Prospective Study Evaluating the Treatment of Hyperdynamic Forehead WrinklesWrinklesNCT01984619Pacira Pharmaceuticals, Inc47
Unknown
1 期
Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole BloodMetastatic CancerNCT03058809Viatar LLC100
已完成
不适用
Clinical Trial of the invisaRED® IR REHAB Device When Used as an Adjunctive Therapy for Nociceptive Musculoskeletal PainNociceptive PainMusculoskeletal PainNCT06393088IR Technology, LLC31